News

August 16, 2019

Immix Cleared to Expand Phase 1/2a Trial of IMX-110 to US Sites

News

A Phase 1/2a trial testing the advanced solid tumor treatment candidate IMX-110 in Australia has been cleared by the U.S. Food and Drug Administration to enroll participants in the United ... Read more

August 14, 2019

Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC

News

Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The open-label ... Read more

August 12, 2019August 27, 2019

Optimal Just-in-Time Approach Accelerates Enrollment in Trials

News

Using an approach called Optimal Just-in-Time (JIT) has shortened the start of patient enrollment in clinical trials of both solid tumors and blood cancers from eight months to only two ... Read more

August 9, 2019September 10, 2019

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

News

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking ... Read more

August 7, 2019

Pre-cancerous Lesions Do Not Always Lead to Ovarian Cancer, Study Finds

News

Not all “pre-cancerous” ovarian lesions progress to full-fledged cancer, a new study reports. If confirmed, these results could allow for better identification of ovarian cancer at its very early stages, ... Read more

August 5, 2019

$566K Grant Will Support Research on Use of Contraceptive Pill to Prevent Ovarian Cancer

News

A $566,000 grant, awarded via the Ovarian Cancer Research Foundation, will support research in Australia that aims to establish the use of contraceptive pills as an effective strategy for preventing ... Read more

August 2, 2019August 26, 2019

Gray Foundation Awards $3.75M to Study of BRCA Mutations in Ovarian and Other Cancers

News

The Gray Foundation awarded a $3.75 million grant to a researcher team to study how BRCA1 or BRCA2 mutations, along with other genetic anomalies, increase the risk of breast, ovarian, ... Read more

July 31, 2019August 26, 2019

NHS England to Cover Lynparza Earlier in Advanced OC Treatment

News

Maintenance treatment with Lynparza (olaparib) is now recommended after response to the first round of platinum-based chemotherapy in women with advanced ovarian cancer on England’s National Health Service (NHS). The decision by ... Read more

July 29, 2019

BRCA Testing for Ovarian Cancer Patients Could Be Decided by Family History and Age, Study Suggests

News

Women with ovarian cancer who have a family history of breast or ovarian cancer, and are younger than 45 if breast cancer in a near relative makes up that history, are ... Read more

July 26, 2019

UPMC, Helomics Join to Develop Predictive Models of Ovarian Cancer Outcomes

News

Researchers from the University of Pittsburgh Medical Center (UPMC) have teamed up with Helomics — a subsidiary of Predictive Oncology — to explore the use of artificial intelligence as a ... Read more